SBFM · Sunshine Biopharma Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 1, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 1, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SBFM
this stock
Sunshine Biopharma Inc.
|
$4.50M | — | +4.1% | — | 3.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.06B | +16.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.82B | +3.3% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.94B | -1.1% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 2.1%
- Net QoQ
- +44.4K sh
- Top holder
- HRT FINANCIAL LP
Performance
Raw-price comparisons begin at the captured split on Jun 1, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SBFM | +0.9% | -30.1% | — | -0.9% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.2% | -33.8% | — | -3.4% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.